Advertisement
Screener

Alpha Cognition Inc. (ACOG) Accretion Expense

2.8 / 5 stars · 68/120 Roast Me

Alpha Cognition Inc. Accretion Expense

Alpha Cognition Inc. (ACOG) reported Accretion Expense of $4.89 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AccretionExpense · last filed 2025-11-13

  • Alpha Cognition Inc. accretion expense for the quarter ending 2025-09-30 was $0.00.
  • Alpha Cognition Inc. accretion expense for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
  • Alpha Cognition Inc. accretion expense for the quarter ending 2025-03-31 was $4.89K, a 70.54% decline year-over-year.
  • Alpha Cognition Inc. accretion expense for the quarter ending 2024-12-31 was $42.75K, a 154.54% increase year-over-year.
  • Alpha Cognition Inc. accretion expense for fiscal 2024 was $80.50K, a 34.67% increase from fiscal 2023.
  • Alpha Cognition Inc. accretion expense for fiscal 2023 was $59.78K.
Period endAccretion Expense 3 monthAccretion Expense 6 monthAccretion Expense 9 monthAccretion Expense 9 month as first filedAccretion Expense 12 month
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$0.00
derived: sum of 2 quarters · filed 2025-11-13
$4.89K
10-Q · filed 2025-11-13
$47.64K
derived: sum of 4 quarters · filed 2025-11-13
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$4.89K
10-Q · filed 2025-08-14
$47.64K
derived: sum of 3 quarters · filed 2025-08-14
$47.64K
derived: sum of 4 quarters · filed 2025-11-13
2025-03-31$4.89K
10-Q · filed 2025-05-15
$47.64K
derived: sum of 2 quarters · filed 2025-05-15
$47.64K
derived: sum of 3 quarters · filed 2025-11-13
$68.79K
derived: sum of 4 quarters · filed 2025-11-13
2024-12-31$42.75K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$42.75K
derived: sum of 2 quarters · filed 2025-11-13
$63.89K
derived: sum of 3 quarters · filed 2025-11-13
$80.50K
10-K · filed 2025-03-31
2024-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$21.14K
derived: sum of 2 quarters · filed 2025-11-13
$37.75K
10-Q · filed 2025-11-13
$59.13K
10-Q · filed 2024-11-14
$54.55K
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$21.14K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$37.75K
10-Q · filed 2025-08-14
$54.55K
derived: sum of 3 quarters · filed 2025-08-14
$71.34K
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$16.61K
10-Q · filed 2025-05-15
$33.41K
derived: sum of 2 quarters · filed 2025-05-15
$50.20K
derived: sum of 3 quarters · filed 2025-05-15
2023-12-31$16.80K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$33.59K
derived: sum of 2 quarters · filed 2025-03-31
$59.78K
10-K · filed 2025-03-31
2023-09-30$16.80K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$42.98K
10-Q · filed 2024-11-14
2023-06-30$26.19K
10-Q · filed 2024-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Alector, Inc. (ALEC)United States$0.213B-1.90
Humacyte, Inc. (HUMA)United States$0.155B-2.26
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37